Alb-uPA-transgenic mice, first developed in 1990 to study neonatal bleeding disorders [76], express the hepatotoxic urokinase-type plasminogen activator (uPA) transgene under the control of an albumin promoter causing subacute murine hepatocyte toxicity soon after birth, thus providing a growth advantage for transplanted human hepatocytes. Here, PLAU is linked to hemorrhagic disease.